TGFB1 and neoplasm: Taken together, the results presented here demonstrate the impact of blocking TGFβ signaling and provide a strong incentive to clinically explore the potential of galunisertib treatment to enhance the development of anti-tumor T cell immunity, which may be enhanced by combinations with immune checkpoint inhibitors.